[go: up one dir, main page]

CL2007002533A1 - Sal de {1-metil-5-[2-(5-trifluorometil-1h-imidazol-2-il)-piridin-4-iloxi]-1h-benzoimidazol-2-il}-(4-trifluorometil-fenil)amina; metodo de preparacion; composicion farmaceutica que la comprende; metodo para preparar la composicion; y uso para tratar e - Google Patents

Sal de {1-metil-5-[2-(5-trifluorometil-1h-imidazol-2-il)-piridin-4-iloxi]-1h-benzoimidazol-2-il}-(4-trifluorometil-fenil)amina; metodo de preparacion; composicion farmaceutica que la comprende; metodo para preparar la composicion; y uso para tratar e

Info

Publication number
CL2007002533A1
CL2007002533A1 CL200702533A CL2007002533A CL2007002533A1 CL 2007002533 A1 CL2007002533 A1 CL 2007002533A1 CL 200702533 A CL200702533 A CL 200702533A CL 2007002533 A CL2007002533 A CL 2007002533A CL 2007002533 A1 CL2007002533 A1 CL 2007002533A1
Authority
CL
Chile
Prior art keywords
trifluorometil
composition
benzoimidazol
imidazol
phenyl
Prior art date
Application number
CL200702533A
Other languages
English (en)
Inventor
Rampurna Hashash Ah Gullapalli
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of CL2007002533A1 publication Critical patent/CL2007002533A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CL200702533A 2006-08-30 2007-08-30 Sal de {1-metil-5-[2-(5-trifluorometil-1h-imidazol-2-il)-piridin-4-iloxi]-1h-benzoimidazol-2-il}-(4-trifluorometil-fenil)amina; metodo de preparacion; composicion farmaceutica que la comprende; metodo para preparar la composicion; y uso para tratar e CL2007002533A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84117706P 2006-08-30 2006-08-30
US95446607P 2007-08-07 2007-08-07

Publications (1)

Publication Number Publication Date
CL2007002533A1 true CL2007002533A1 (es) 2008-02-08

Family

ID=39027583

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702533A CL2007002533A1 (es) 2006-08-30 2007-08-30 Sal de {1-metil-5-[2-(5-trifluorometil-1h-imidazol-2-il)-piridin-4-iloxi]-1h-benzoimidazol-2-il}-(4-trifluorometil-fenil)amina; metodo de preparacion; composicion farmaceutica que la comprende; metodo para preparar la composicion; y uso para tratar e

Country Status (33)

Country Link
US (2) US8202998B2 (es)
EP (1) EP2059518B1 (es)
JP (1) JP5279712B2 (es)
KR (1) KR20090043542A (es)
CN (1) CN101516870B (es)
AT (1) ATE504584T1 (es)
AU (1) AU2007290388B2 (es)
BR (1) BRPI0716243A2 (es)
CA (1) CA2660376C (es)
CL (1) CL2007002533A1 (es)
CO (1) CO6150180A2 (es)
CY (1) CY1112187T1 (es)
DE (1) DE602007013774D1 (es)
DK (1) DK2059518T3 (es)
ES (1) ES2360968T3 (es)
GT (1) GT200900045A (es)
HR (1) HRP20110311T1 (es)
IL (1) IL196811A (es)
JO (1) JO2702B1 (es)
MA (1) MA30711B1 (es)
MX (1) MX2009002279A (es)
MY (1) MY161829A (es)
NO (1) NO20091236L (es)
NZ (1) NZ574620A (es)
PE (2) PE20080766A1 (es)
PL (1) PL2059518T3 (es)
PT (1) PT2059518E (es)
RU (1) RU2457206C2 (es)
SI (1) SI2059518T1 (es)
TN (1) TN2009000068A1 (es)
TW (1) TW200819438A (es)
WO (1) WO2008027523A2 (es)
ZA (1) ZA200900664B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080766A1 (es) 2006-08-30 2008-06-15 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen
US8324389B2 (en) * 2007-03-02 2012-12-04 Novartis Ag Solid forms of a Raf kinase inhibitor
AU2009257487B2 (en) * 2008-06-13 2013-01-31 Novartis Ag Substituted benzimidazoles for neurofibromatosis
PL2391366T3 (pl) * 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
WO2011044072A1 (en) 2009-10-05 2011-04-14 Novartis Ag Combination of raf-265 and an activator of ampk for use in the treatment of a proliferative disease
SG190210A1 (en) * 2010-12-03 2013-06-28 Novartis Ag Pharmaceutical compositions
JP7731883B2 (ja) * 2019-12-02 2025-09-01 アストラゼネカ・アクチエボラーグ ６－（２－クロロ－６－メチルピリジン－４－イル）－５－（４－フルオロフェニル）－１，２，４－トリアジン－３－アミンの固形製剤処方物
WO2022083741A1 (zh) * 2020-10-23 2022-04-28 上海辉启生物医药科技有限公司 吡唑并吡啶类化合物或其盐及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299108B2 (en) * 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
ATE447404T1 (de) * 2002-03-29 2009-11-15 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
US20060189619A1 (en) 2005-02-24 2006-08-24 Wyeth 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds
TWI387592B (zh) * 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
US7731795B2 (en) 2005-12-02 2010-06-08 Clemson University Rhombohedral fluoroberyllium borate crystals and hydrothermal growth thereof for use in laser and non-linear optical applications and devices
US8455662B2 (en) * 2006-07-21 2013-06-04 Novartis Ag Formulations for benzimidazolyl pyridyl ethers
PE20080766A1 (es) * 2006-08-30 2008-06-15 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen

Also Published As

Publication number Publication date
DE602007013774D1 (de) 2011-05-19
CN101516870A (zh) 2009-08-26
RU2009111384A (ru) 2010-10-10
US20100168060A1 (en) 2010-07-01
MX2009002279A (es) 2009-03-20
NO20091236L (no) 2009-03-27
ZA200900664B (en) 2009-12-30
JO2702B1 (en) 2013-03-03
HRP20110311T1 (hr) 2011-08-31
DK2059518T3 (da) 2011-05-16
PE20080766A1 (es) 2008-06-15
SI2059518T1 (sl) 2011-06-30
AU2007290388B2 (en) 2011-07-14
NZ574620A (en) 2011-05-27
PL2059518T3 (pl) 2011-09-30
CO6150180A2 (es) 2010-04-20
US20120308651A1 (en) 2012-12-06
WO2008027523A3 (en) 2008-04-10
PE20130814A1 (es) 2013-08-08
CY1112187T1 (el) 2015-12-09
TN2009000068A1 (en) 2010-08-19
TW200819438A (en) 2008-05-01
CA2660376C (en) 2014-04-15
RU2457206C2 (ru) 2012-07-27
MY161829A (en) 2017-05-15
JP2010502622A (ja) 2010-01-28
HK1131613A1 (en) 2010-01-29
IL196811A0 (en) 2009-11-18
US8501785B2 (en) 2013-08-06
BRPI0716243A2 (pt) 2013-09-03
MA30711B1 (fr) 2009-09-01
US8202998B2 (en) 2012-06-19
PT2059518E (pt) 2011-07-11
EP2059518A2 (en) 2009-05-20
WO2008027523A2 (en) 2008-03-06
ES2360968T3 (es) 2011-06-10
CN101516870B (zh) 2013-09-11
IL196811A (en) 2013-03-24
KR20090043542A (ko) 2009-05-06
GT200900045A (es) 2010-06-14
JP5279712B2 (ja) 2013-09-04
EP2059518B1 (en) 2011-04-06
ATE504584T1 (de) 2011-04-15
AU2007290388A1 (en) 2008-03-06
CA2660376A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
CL2007002533A1 (es) Sal de {1-metil-5-[2-(5-trifluorometil-1h-imidazol-2-il)-piridin-4-iloxi]-1h-benzoimidazol-2-il}-(4-trifluorometil-fenil)amina; metodo de preparacion; composicion farmaceutica que la comprende; metodo para preparar la composicion; y uso para tratar e
BRPI1008396B8 (pt) composto de sal de tosilato de um derivado de 5-pirazolil-2-piridona, composição farmacêutica, uso e processo para preparação do dito composto
EA201100030A1 (ru) Пиразольные соединения 436
CL2012001391A1 (es) Compuestos derivados de triazolopiridina sustituidos, inhibidores de la quinasa mps-1; composición farmacéutica; procedimiento de preparacion; combinación farmacéutica y uso para la profilaxis o tratamiento de una enfermedad hiperproliferativa tal como tumores hematológicos, sólidos y/o sus metástasis; compuestos intermediarios.
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
DOP2014000133A (es) Triazolopiridinas sustituidas
BRPI0813237A2 (pt) Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
CL2008000403A1 (es) Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos.
DOP2010000326A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
NZ600801A (en) Substituted imidazopyridinyl-aminopyridine compounds
BR112013026935A2 (pt) preparação de base aquosa, composição para limpeza de superfícies de materiais refratários e uso da composição
ECSP12012338A (es) Triazolopiridinas sustituidas
DOP2013000244A (es) Triazolopiridinas
CL2009001298A1 (es) Compuestos derivados de n-ciclohexil-2-fenoxinicotinamida; composición farmcéutica que los comprende; combinación farmacéutica que los comprende; y su uso para tratar una enfermedad mediada por la pde4.
CL2008001323A1 (es) Compuestos derivados de triazolil aminopiridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
BR112013033568A2 (pt) compostos éter amidopiridil e composições e seu uso contra parasitas
UY31839A (es) Compuestos
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
UY30087A1 (es) Piperazinas y piperidinas como potenciadoras de mglur5
MA32628B1 (fr) Agents antifongiques
BR112016013974A2 (pt) Composto, composição farmacêutica, uso da composição farmacêutica e uso do composto
RU2013110517A (ru) Средство для профилактики или лечения неалкогольного стеатогепатита
DOP2012000228A (es) Procedimiento para la preparación de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida
AR062591A1 (es) Sales de benzimidazolil piridil eteres y formulaciones que las contienen
WO2006099479A3 (en) Methods of treating cancer using ppar-gamma antagonists